Unió Europea - alemany - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - impfstoffe - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. der einsatz dieses impfstoffs sollte in übereinstimmung mit den offiziellen empfehlungen.

Alemanya - alemany - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

marien-apotheke rudolf glasl (114034) - lebertran ((o.w.a.)); zinksalbe - salbe - lebertran ((o.w.a.)) (178) 12,5 gramm; zinksalbe (363) 25 gramm

Unió Europea - alemany - EMA (European Medicines Agency)

chemical works of gedeon richter plc. (gedeon richter plc.) - ganirelix acetate - reproductive techniques, assisted; ovulation induction; infertility, female - hormone und analoga der hypophyse und des hypothalamus - prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation (coh) for assisted reproduction techniques (art).

Suïssa - alemany - Swissmedic (Swiss Agency for Therapeutic Products)

ibsa institut biochimique sa - menotropinum - polvere e soluzione per soluzione iniettabile - praeparatio cryodesiccata: menotropinum 900 u.i., lactosum monohydricum, polysorbatum 20, dinatrii phosphas dihydricus corresp. natrium 0.1 mg, acidum phosphoricum, natrii hydroxidum, pro vitro. solvens: metacresolum, aqua ad iniectabile. - störungen der ovulation, reproduktionsmedizin - biotechnologika

Unió Europea - alemany - EMA (European Medicines Agency)

merck sharp dohme limited - lamivudin, raltegravir-kalium - hiv-infektionen - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - dutrebiszusammen werden in kombination mit anderen anti‑retroviral arzneimitteln für die behandlung des humanen immundefizienz-virus (hiv‑1)-infektion bei erwachsenen, jugendlichen und kindern ab einem alter von 6 jahren und mit einem gewicht von mindestens 30 kg ohne gegenwart oder vergangenheit angegeben. nachweis der viralen resistenz gegen antivirale mittel des insti (integrase strang übertragen hemmer) und nrti (nukleosid-reverse-transkriptase-hemmer) klassen (siehe abschnitte 4. 2, 4. 4 und 5.

Alemanya - alemany - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

berlin-chemie aktiengesellschaft (4000014) - pankreas-pulver vom schwein - magensaftresistente hartkapsel - teil 1 - magensaftresistente hartkapsel; pankreas-pulver vom schwein (01015) 319,052 milligramm

Suïssa - alemany - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - enfuvirtidum - injektionslösung - praeparatio cryodesiccata: enfuvirtidum 90 mg, natrii carbonas, mannitolum, natrii hydroxidum aut acidum hydrochloridum, pro vitro corresp. natrium 1.037 mg. solvens: aqua ad iniectabile pro vitro. - hiv-infektionen - synthetika

Suïssa - alemany - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - regorafenibum - filmtabletten - regorafenibum 40 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 14.01 mg, magnesii stearas, povidonum, silica colloidalis anhydrica, Überzug: lecithinum ex soja, macrogolum 3350, poly(alcohol vinylicus), talcum, e 172 (rubrum), e 172 (flavum), e 171, pro compresso obducto. - metastasiertes kolorektalkarzinom, gastrointestinale stromatumoren, leberzellkarzinom - synthetika

Suïssa - alemany - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ceritinibum - kapseln - ceritinibum 150 mg, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, carboxymethylamylum natricum a corresp. natrium 1.98 mg, magnesii stearas, silica colloidalis anhydrica, kapselhülle: gelatina, e 171, e 132, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio 28 per centum, pro capsula. - onkologikum - synthetika

Alemanya - alemany - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

allergan pharmaceuticals international limited (8164913) - pankreas-pulver vom schwein - magensaftresistente hartkapsel - teil 1 - magensaftresistente hartkapsel; pankreas-pulver vom schwein (01015) 89,32 milligramm